

McCoy books and publications, the installation newspaper (The Real McCoy) and community outreach to ensure that Fort McCoy remains a great community partner and neighbor. Probably her most lasting impact at Fort McCoy is her role in the creation of the installation's Commemorative Area, History Center and Equipment Park. Under Linda's supervision, the Fort McCoy Commemorative Area was recognized with a Department of the Army Award of Excellence in the 2009 Major General Keith L. Ware Public Affairs Communications Competition and specifically cited for its Community Relations outreach.

It has been an honor for me to serve as U.S. Representative for Wisconsin's Third Congressional District during the Fournier's tenure at Fort McCoy. I know their leadership will be greatly missed at the base and surrounding communities, but I am thankful for their dedication and contributions to ensuring that Fort McCoy remains a shining star in the nation's military training infrastructure.

On behalf of my constituents in Wisconsin and a grateful nation, I would like to thank and commend Al and Linda Fournier for their decades of dedicated service with the U.S. Army Reserve at Fort McCoy and wish them the very best in their future endeavors.

CONGRATULATING DR. YUICHI SHODA, GOLDEN GOOSE AWARDEE

HON. SUZAN K. DELBENE

OF WASHINGTON

IN THE HOUSE OF REPRESENTATIVES

Thursday, September 17, 2015

Ms. DELBENE. Mr. Speaker, I rise today to congratulate University of Washington Professor Dr. Yuichi Shoda on being recognized this week as a recipient of the 2015 Golden Goose Award.

Created in 2012, the Golden Goose Award celebrates obscure science to show how basic research—even research that may sound odd—can lead to major breakthroughs and significant impacts on society.

Dr. Shoda's work with the "Marshmallow Test," first funded by the National Institutes of Health in the 1960s to test a child's self-control, is more than deserving of this honor. His test was seminal in interpreting human behavior and has impacted how we educate children and save for retirement today.

Each year, federal investments in research like this help push the boundaries of scientific knowledge, support new industries and address the challenges facing our country.

But to remain a world leader, we need to ensure our researchers and institutions continue to have the tools to explore new ideas and frontiers in research, as well as the funding opportunities to do so.

Unfortunately, research continues to face irresponsible funding cuts in Congress. When sequestration took effect two years ago, more than 1,000 grants at the National Science Foundation went unfunded, and NIH funding was slashed by \$1.6 billion.

It's time we learn that research isn't a spigot that can just be turned on and off. Breakthroughs come after years of incremental research, and cutting funds now could set us back for decades to come.

Through my post-graduate research work, I have also seen firsthand the economic impact of these investments in communities nationwide. In my home state of Washington, for example, funding for NIH supports more than 14,000 jobs.

I hope this week's recognition of obscure science by the Golden Goose Awards helps renew our commitment to research. We must support the tireless efforts of those who allow our country to continue to break new ground in scientific discovery.

Congratulations to Dr. Shoda and the other Golden Goose Awardees, and thank you for your continued contributions to our nation.

RECOGNIZING NATIONAL NEUROBLASTOMA AWARENESS DAY

HON. MICHAEL T. McCAUL

OF TEXAS

IN THE HOUSE OF REPRESENTATIVES

Thursday, September 17, 2015

Mr. McCAUL. Mr. Speaker, I rise today to recognize September 20th as National Neuroblastoma Awareness Day. Neuroblastoma is a deadly pediatric cancer that primarily strikes infants and young children. Of the 15,780 new cases of pediatric cancer in the U.S. each year, approximately 700 are neuroblastoma diagnoses. About half of these children will have an advanced-stage, high-risk form of disease. Even with aggressive treatment, only 40 to 50 percent of high-risk patients will survive. Neuroblastoma is the most common extra-cranial solid tumor among children and the most common cancer in infancy. The cause of the disease is unknown but leads to abnormal cell growth during the development of the sympathetic nervous system.

I am pleased to inform my colleagues that we have seen significant progress this year in the fight against this devastating disease. In March, the Food and Drug Administration approved the first drug ever to treat children with high-risk neuroblastoma. In August, the same product received regulatory approval in the European Union. The drug, Unituxin (dinutuximab), is marketed by United Therapeutics Corporation. United Therapeutics was also granted a Pediatric Rare Disease Priority Review Voucher by the FDA. This innovative voucher program was established by the Creating Hope Act—legislation that I sponsored with my colleagues Congressman CHRIS VAN HOLLEN (D-MD) and Congressman G.K. BUTTERFIELD (D-NC). Enacted into law in 2012, the Creating Hope Act is designed to incentivize the pharmaceutical industry to invest in new therapies for rare childhood diseases.

Approval of this groundbreaking therapy is the result of a unique public-private partnership over many years. Originally developed by Dr. Alice Yu, University of California San Diego, the drug was tested in high-risk neuroblastoma patients in clinical studies conducted by the Children's Oncology Group through support from the National Cancer Institute (NCI). Manufacturing of the complex chimeric antibody was conducted by the NCI at its biopharmaceutical laboratory in Frederick, Maryland. In 2010, United Therapeutics entered into a Cooperative Research and Develop-

ment Agreement with the NCI where the company assumed responsibility for manufacturing the drug and moving it through the regulatory approval process.

According to Dr. Malcolm Smith, Associate Branch Chief, Pediatrics in the Cancer Therapy Evaluation Program at NCI, "The FDA approval of dinutuximab represents the culmination of a remarkably productive collaboration between researchers of the NCI-supported Children's Oncology Group, the manufacturing and clinical research groups of NCI, and the oncology team at United Therapeutics. Children with neuroblastoma will benefit from this collaboration, and the drug development pathway blazed by dinutuximab will likely be followed in the future to develop other novel agents directed against pediatric cancer therapeutic targets."

Mr. Speaker, I have the privilege of co-chairing the Congressional Childhood Cancer Caucus with Congressman VAN HOLLEN. Each September, the Caucus commemorates National Childhood Cancer Awareness Month by hosting a Childhood Cancer Summit on Capitol Hill. This event features pediatric cancer patients, advocates, physicians, industry partners and other key stakeholders. As part of this year's Summit on September 18th, we will hear from Casey and Lesley Ryan, the parents of Rex Ryan, a young neuroblastoma patient from my home state of Texas. We will also hear from Roger Jeffs, PhD, President and Co-Chief Executive Officer of United Therapeutics, Dr. Lee Helman from the National Cancer Institute, Dr. Michael Link of the Stanford School of Medicine, Dr. Amy Fowler of the Dell Children's Medical Center, and Danielle Leach of the St. Baldrick's Foundation.

As we recognize the progress that has been made in neuroblastoma treatment, we remain focused on the many challenges that remain and the toll this disease has taken on so many families. One such family is the Lindbergs from Germantown, Maryland. Wendy and Gavin Lindberg lost their 7 year-old son Evan to neuroblastoma in 2010. He was their only child. Diagnosed at the age of 3, Evan waged a four-year battle against Stage IV neuroblastoma that defined courage. Evan was a remarkable little boy who inspired everyone he met with his bravery, compassion and joyful approach to life.

In his memory, Wendy and Gavin established The Evan's Victory Against Neuroblastoma Foundation to promote awareness of the disease, fund much-needed research, and support patient wellness programs for children in treatment. Since Evan's passing, the Foundation bearing his name has made and continues to make a real difference in the lives of children and families suffering from neuroblastoma. There are many other organizations doing wonderful philanthropic work in memory of children lost far too young to this terrible disease. Their strength in the face of adversity compels us to do all we can to help families facing the unthinkable.

So Mr. Speaker, I am proud to rise in recognition of September 20th as National Neuroblastoma Awareness Day and encourage my colleagues to join in the fight against all pediatric cancers. Our children's future depends on it.